Q-omics provides the consensus-scored MIR7974 profile across patient tissues and cancer cell-line models. MIR7974 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, MIR7974 is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, MIR7974 RNA expression shows 11,746 significant gene co-expression associations, with the highest sampling consensus in DLBC. Together, these results highlight READ, BRCA, and DLBC as cancer lineages where MIR7974 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR7974 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR7974 survival associations across molecular data types. MIR7974 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR7974 RNA expression–survival associations across cancer types. High MIR7974 expression shows unfavorable associations in READ, COAD, LUAD, LUSC and KICH, but favorable associations in STAD. The READ Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify READ as the clearest survival context for MIR7974 RNA expression.
This table summarizes MIR7974 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR7974. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR7974 shows lower tumor expression in BRCA and higher tumor expression in COAD. The BRCA box plot shows higher MIR7974 RNA expression in normal versus tumor tissue (log2 FC = −0.155, t-test p = .002).
This table shows molecular features associated with MIR7974 in patient tissues and cancer cell lines. In patient samples, MIR7974 shows the broadest associations at the RNA and protein expression levels, with DLBC recurring as the lineage with the largest associated feature set.
